San Francisco, CA, United States of America

Christopher S Regens

This inventor holds 9 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 2 EPO patents. Top assignees: Gilead Sciences, Inc., Bristol-Myers Squibb Compnay. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher S Regens. Retrieved from https://idiyas.com/inventor/christopher-s-regens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 2 (Patent Applications = 8)

Average Co-Inventor Count = 10.2

ph-index = 3

Forward Citations = 21(Granted Patents)

Company Filing History:

8 out of 946

Gilead Sciences, Inc.

patents

1 out of 3,737

Bristol-Myers Squibb Compnay

patents

Years Active: 2016-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12590089 - Processes for preparing toll-like receptor modulator compounds (2026-03-31),

2. 12410146 - Processes and intermediates for preparing MCL1 inhibitors (2025-09-09),

3. 12202782 - Processes and intermediates for preparing MCL1 inhibitors (2025-01-21),

4. 12162896 - Salts and polymorphs of certain MCL-1 inhibitors (2024-12-10),

5. 11760736 - Processes and intermediates for preparing MCL1 inhibitors (2023-09-19),

6. 11583531 - Solid forms of a toll-like receptor modulator (2023-02-21),

7. 11325891 - Processes and intermediates for preparing MCL1 inhibitors (2022-05-10),

8. 11286257 - Processes for preparing toll-like receptor modulator compounds (2022-03-29),

9. 9518058 - Process for the preparation of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (2016-12-13),

Title: Christopher S Regens: Innovator in MCL1 Inhibitors

Introduction

Christopher S Regens is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of medicinal chemistry, particularly in the development of MCL1 inhibitors. With a total of 8 patents to his name, Regens has established himself as a key figure in the pharmaceutical industry.

Latest Patents

Regens' latest patents focus on processes and intermediates for preparing MCL1 inhibitors. The first patent provides methods for preparing MCL1 inhibitors or a salt thereof, along with related key intermediates. The second patent relates to methods and intermediates for the synthesis of certain compounds that inhibit MCL1, aimed at treating various cancers. These innovations are crucial for advancing cancer treatment options.

Career Highlights

Throughout his career, Christopher S Regens has worked with leading companies in the pharmaceutical sector, including Gilead Sciences, Inc. and Bristol-Myers Squibb Company. His experience in these organizations has allowed him to contribute to groundbreaking research and development efforts.

Collaborations

Regens has collaborated with notable professionals in his field, including Michael A Ischay and Jeffrey E Merit. These partnerships have further enhanced his work and the impact of his inventions.

Conclusion

Christopher S Regens is a distinguished inventor whose work on MCL1 inhibitors is paving the way for new cancer therapies. His contributions to the pharmaceutical industry are invaluable and continue to influence the field of medicinal chemistry.

Profile summary based on public USPTO records.